Can HPV typing predict the behaviour of cervical epithelial neoplasia?

Histopathology

Volumn 31, Issue 4, 1997, Pages 301-303

  Herrington, C S ^a   Wells, M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cervix; Human papillomavirus; Neoplasia

Indexed keywords

VIRUS DNA;

CANCER INVASION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS TYPING; WART VIRUS;

EID: 0030769886     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1997.2340846.x     Document Type: Review

References (38)

1. Herrington CS. Human papillomaviruses and cervical neoplasia I: classification, virology, pathology and epidemiology. J. Clin. Pathol. 1994: 47; 1066 - 1072.
2. Herrington CS. Human papillomaviruses and cervical neoplasia II: interaction with other factors. J. Clin. Pathol. 1995; 48; 1 - 6.
3. Herrington CS, Evans MF, Hallam NF, Charnock FM, Gray W, McGee JO'D. HPV status in the prediction of high grade CIN in patients with persistent low grade cervical cytological abnormalities. Br. J. Cancer 1995; 71; 206 - 209.
4. Aziz DC, Ferre F, Robitaille J, Ferenczy A. Human papillomavirus testing in the clinical laboratory 1: squamous lesions of the cervix. J. Gynecol. Surg. 1993; 9: 1 - 7.
5. Dürst M, Kleinheinz A, Holtz M, Gissmann L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J. Gen Virol 1985; 66; 1515 - 1522.
6. Cooper K, Herrington CS, Stickland JE et al. Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isotopic in situ hybridisation. J. Clin. Pathol. 1991; 44: 990 - 996.
7. Kristiansen E, Jenkins A, Holm R. Coexistence of episomal and integrated HPV 16 DNA in squamous carcinoma of the cervix. J. Clin. Pathol. 1994; 47; 253 - 256.
8. Berumen J, Unger E, Casas L, Figueroa P. Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. Hum Pathol. 1995; 26; 676 - 681.
9. Gomez F, Picazo A, Roldan M et al. Labelling pattern obtained by non-isotopic in situ hybridization as a prognostic factor in HPV-associated lesions. J. Pathol. 1996: 179; 272 - 275.
10. Cooper K, McGee JO'D. Human papillomavirus. integration and cervical carcinogenesis: a clinicopathological perspective. J. Clin. Pathol. Mol. Pathol. 1997: 50; 1 - 3.
11. Rose BR, Thompson CH, Simpson JM et al. Human papillomavirus deoxyribonucleic acid as a prognostic indicator in early stage cervical cancer: a possible role for type 18. Am. J. Obstet. Gynecol. 1995: 173; 1461 - 1468.
12. Abeler VM, Holm R, Nesland JM, Kjorstad KE. Small cell carcinoma of the cervix - a clinipathological study of 26 patients. Cancer 1994: 73; 672 - 677.
13. Hecht JL, Kadish AS, Jiang G, Burk RD. Genetic characterisation of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a sub-type with decreased oncogenic potential. Int. J. Cancer 1995; 60; 369 - 376.
14. Park JS, Chee YH, Mankoong SE et al. Human papillomavirus detection in cervical carcinoma tissues and para-aortic lymph nodes by the polymerase chain reaction. Gynecol. Oncol. 1994: 53; 344 - 351.
15. Park JS, Rhyu KS. Kim CJ et al. Presence of oncogenic HPV DNAs in cervical carcinoma tissues and pelvic lymph nodes associating with proliferating cell nuclear antigen expression. Gynecol. Oncol. 1996; 60; 418 - 423.
16. Kedzia H, Godzicka-Jozefiak A, Kedzia W, Poreba E. The value of the presence of HPV 16 in pelvic lymph nodes of cervical cancer patients. Eur. J. Gynaec. Oncol. 1996: 16; 199 - 202.
17. Hording U, Ravn V, Knudsen J, Visfeldt J. The use of polymerase chain reaction to detect metastatic cancer cells within lymph nodes in stage I cervical carcinoma. Int. J. Gynecol. Pathol. 1995: 14; 339 - 343.
18. Cuzick J, Szarewski A, Terry G et al. Human papillomavirus testing in primary cervical screening. Lancet 1995: 345; 1533 - 1536.
19. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia. Lancet 1992: 339; 959 - 960.
20. Bavin PJ, Giles JA. Deery A et al. Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report. Br. J. Cancer 1993; 67; 602 - 605.
21. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br. J. Cancer 1994: 69; 167 - 171.
22. Herrington CS, Evans MF, Gray W, McGee JO'D, Hallam NF, Charnock FM. HPV 16 DNA and prediction of high grade CIN. Lancet 1992: 339; 1352 - 1353.
23. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cell of undetermined significance. Am. J. Obstet. Gynecol. 1995: 172; 946 - 954.
24. Schneider A, Zahm DM, Kirchmayr R, Schneider VL. Screening for cervical intraepithelial neoplasia grade 2/3 - validity of cytologic study, cervicography and human papillomavirus detection. Am. J. Obstet. Gynecol. 1996: 174; 1534 - 1541.
25. Herrington CS, Evans MF, Charnock FM, Gray W, McGee JO'D. HPV testing in patients with low-grade cervical cytological abnormalities - a follow-up study. J. Clin. Pathol. 1996: 49; 493 - 496.
26. Jacobs MV, Snijders PJF, van den Brule AJC, Helmerhorst TJM, Meijer CJLM, Walboomers JMM. A general primer GP5+/GP6+ mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 1997: 35; 791 - 795.
27. Ho GYF. Burk RD. Klein S et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 1995: 87; 1365 - 1371.
28. Remmink AJ, Walboomers JMM. Helmerhorst TJM et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease - natural history up to 36 months. Int. J. Cancer 1995: 61: 306 - 311.
29. Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996: 77; 121 - 127.
30. Meijer CJLM, van den Brule AJ, Snijders PJ, Heimerhorst T, Kenemans P, Walboomers JMM. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci. Publ 1992: 119; 271 - 281.
31. Jenkins D, Sherlawjohnson C, Gallivan S. Can papillomavirus testing be used to improve cervical cancer screening? Int. J. Cancer 1996; 65; 768 - 773.
32. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: a Basic Science for Clinical Medicine. 2nd ed. Boston: Little, Brown & Co., 1991.
33. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer - a worldwide perspective. J. Natl. Cancer Inst 1995: 87; 796 - 802.
34. Burger MPM, Hollema H, Pieters WJLM, Schroder FP. Quint WGV. Epidemiological evidence of cervical intraepithelial neoplasia without the presence of human papillomavirus. Br. J. Cancer 1996: 73; 831 - 836.
35. Burger MP, Hollema H, Gouw AS, Pieters WJ, Quint WG. Cigarette smoking and human papillomavirus in patients with reported cervical cytological abnormality. Br. Med. J. 1993; 306: 749 - 752.
36. Mehal WZ, Lo DY-M. Herrington CS et al. Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis. J. Clin. Pathol. 1994: 47; 1077 - 1081.
37. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Human papillomavirus-associated cervical intrapithelial neoplasiaa is determined by specific HLA DR-DQ alleles. Int J. Cancer 1996: 67; 595 - 602.
38. Kjaer SK, van den Brule AJC, Bock JE et al. Human papillomavirus - the most significant risk determinant of cervical intraepithelial neoplasia. Int J. Cancer 1996: 65; 601 - 606.